Peptides
GLP-1s Beyond the Scale: The Real Risk-Benefit Ledger for Lifters
Semaglutide-class drugs are rewriting cardiometabolic medicine — and quietly accumulating a safety file that gym-goers should actually read.
peptides
Peptides
GLP-1s Go Under the Knife: What New Surgical Data Mean for Ozempic-Class Users
Fresh cohort analyses say the perioperative picture is procedure-specific — reassuring at the hip, worrying at the shoulder — and shortages keep complicating the calculus.
Peptides
The New GLP-1 Frontier: Combo Stacks, Cardio Synergy, and the Oral Pill Race
GLP-1s aren't just a shred-cycle headline anymore. The next wave — liver-targeting combos, cardiovascular synergy with training, and oral delivery — is rewriting what these peptides can do.
Peptides
The Next GLP-1 Frontier: Oral Pills, Muscle Loss, and the Mind
As the GLP-1 class expands beyond weekly injections, three new studies sketch a more complicated risk-benefit map than the headline weight-loss numbers suggest.
Peptides
Semaglutide's Cardiovascular Dividend: What the Latest Meta-Analyses Reveal
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.
Regenerative & Future Medicine
PRP, Stem Cells, and Peptides: Where Regenerative Orthopedics Actually Has Evidence
A 2025 review of 160 studies grades four regenerative modalities for joint and tendon care. The signal is real — but uneven, and narrower than the marketing suggests.
Peptides
The Quiet Risk in the Peptide Boom: Immunogenicity and What Compounding Pharmacies Don't Test For
Synthetic peptides now account for more than 1 in 10 new FDA-approved chemical entities. The frontier safety question isn't potency — it's what your immune system makes of the molecule, and the impurities riding alongside it.
Peptides
The Next GLP-1s: Dual Fatty-Acid Conjugates and Combo Therapies Push Past Semaglutide
Two 2025 preclinical studies hint at where this class is heading — longer-acting molecules, beta-cell-protective stacks, and the first real challengers to semaglutide's throne.
Peptides
Peptides Go Programmable: AI Diffusion Models Are Designing the Next Therapeutic Wave
A new class of generative models is treating peptide design like a search problem — and the early outputs hint at a faster, more targeted pipeline behind a quarter of all pharma.
Peptides
The GLP-1 Side-Effect File: New Signals on Surgery, Pancreatitis, and the Gallbladder
Semaglutide and tirzepatide are reshaping body composition for millions of lifters and dieters. A cluster of 2025 reports is starting to map what happens when these drugs collide with surgery, scopes, and scans.